Showing results (221-230 of 242) with videos related to
Sort By:
Pageof 25
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2014
Incorporation of pazopanib in maintenance therapy of ovarian cancerAndreas du Bois, Anne Floquet, Jae-Weon Kim, et al.Nature Communications|November 5, 2025
Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trialChee Khoon Lee, Apriliana E R Kartikasari, Nirashaa T Bound, et al.Genes, Chromosomes & Cancer|December 12, 2007
Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumorsRachel Linger, Darshna Dudakia, Robert Huddart, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2017
Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based OutreachGoli Samimi, Marcus Q Bernardini, Lawrence C Brody, et al.Cancer Discovery|June 8, 2017
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaOlga Kondrashova, Minh Nguyen, Kristy Shield-Artin, et al.The New England Journal of Medicine|September 29, 2019
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian CancerRobert L Coleman, Gini F Fleming, Mark F Brady, et al.Human Molecular Genetics|January 13, 2006
Genome-wide linkage screen for testicular germ cell tumour susceptibility lociGillian P Crockford, Rachel Linger, Sarah Hockley, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2024
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast CancerPatricia A Ganz, Hanna Bandos, Tanja Španić, et al.Nature Genetics|December 1, 2022
The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancerDale W Garsed, Ahwan Pandey, Sian Fereday, et al.Canadian Journal of Surgery. Journal Canadien De Chirurgie|June 27, 2023
Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysisTaymaa May, Marcus Bernardini, Stephanie Lheureux, et al.Pageof 25